Structure Therapeutics Launches Phase 1 Trial of Oral Amylin Agonist ACCG-2671 for Obesity
I'm PortAI, I can summarize articles.
Structure Therapeutics Inc. has initiated a Phase 1 clinical trial for ACCG-2671, an oral amylin receptor agonist aimed at treating obesity. The trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of ACCG-2671 in healthy volunteers and individuals with obesity. This study aims to improve scalability, combinability, and patient access to obesity treatments. Results are pending.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments